Mise au point sur le traitement médical du cancer du rein métastatique
Authors:
- 15 August 2009
- journal article
- Published by Springer Nature in Journal africain du cancer / African Journal of Cancer
- Vol. 1 (3) , 154-158
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Cues for migrationNature, 2003
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Molecular basis of the VHL hereditary cancer syndromeNature Reviews Cancer, 2002
- Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trialThe Lancet, 1999